Collegium Pharmaceutical Inc. (COLL), a specialty pharmaceutical company, saw a steady decline in its share price on Thursday. COLL share price decreased by 0.40%, and as a result, the COLL stock stood at $24.84. In the current market, Collegium Pharmaceuticals shares are changing hands at $20.85, a decrease of 16.06% as quarterly results released by the company missed analyst estimates.
Q2 2021 Results
COLL stock has recently announced the financial results for the second quarter of the fiscal year 2021, which ended 30th June 2021. According to the details, the company’s product namely Xtampza ER generated net revenue of $33 million during the quarter. The net revenue generated by the Nucynta franchise was $49.9 million. The net income was $72.8 million, or $2.06 EPS (basic) and $1.79 EPS (diluted). Overall, the company came out with quarterly earnings of $0.27 per share while analysts were looking for $0.34.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Q1 2021 Results
In early May, the company released financial results for the first quarter of the fiscal year 2021, which ended March 31st, 2021. The company announced that Xtampza ER net revenue stood at $35.4 million for the quarter. The net revenue generated by the Nucynta franchise during the quarter stands at $52.3 million. The net income for the quarter was $15.7 million, or $0.45 EPS (basic) and $0.41 EPS (diluted).
Appointment of CFO
In early May, the company also announced the appointment of Colleen Tupper as the company’s Chief Financial Officer and its Executive Vice President. The appointment became effective on May 24th. Colleen Tupper has experience of 20 years in financial roles at different pharmaceutical companies. Before that appointment, he served as CFO and senior vice president in the US business unit of Takeda. He succeeded Paul Brannelly, who had been CFO since 2015.
COLL Stock 2020 Financial results
In February, the company released full-year 2020 financial details. According to those, the total net revenue company generated during the year was $310 million. It includes the net revenue of $128 million by Xtampza ER and $182 million of the Nucynta franchise. During the preceding year, the company generated total net revenue of $296.7 million. Besides, the net income for the year stood at $26.8 million, while during the preceding year, the company had a net loss of $22.7 million.
Effects of Pandemic on COLL Stock
COVID pandemic did not severely impact the business of Collegium Pharmaceuticals. Having roots in the medical industry, the company largely remained unaffected from the effect of the pandemic, as evident from the fact that it generally remained operational throughout the pandemic. With the lessening of government’s restrictions, the mild effects which affected company have started subsiding, as depicted from its quarterly results.
What lies ahead for COLL Stock?
The company could potentially see burgeoning times in the near future. The EPS for this year is estimated to increase by 212.10%, while for next year, it could increase by 43.31%. Analysts have estimated the revenue of the company for the current year to be $346.3 million, while for next year; it could remain at a level of $381.04 million. These positive financial results could impart their influence on COLL stock. So, potential investors should keep a close watch on COLL stock’s performance.